Myasthenia gravis (MG)
Vifor Pharma partner: F. Hoffmann-La Roche Ltd
Product name: CellCept
Generic name: Mycophenolate Mofetil (MMF)
Approved indications: The prevention of rejection of kidney, heart and liver transplants.
Clinical study summary: Randomized, double-blind placebo controlled clinical trial designed to investigate the efficacy and safety of CellCept for patients with myasthenia gravis over a treatment period over 36 weeks.
Primary endpoint: The primary endpoint of responder status encompasses both minimal disease activity and low steroid dose.
Phase of development: Phase III
Trial initiation (first patient enrolled): April 2004
Trial complete: failed to meet both primary and secondary endpoints.
Back to 'Autoimmune Diseases'
Product name: CellCept
Generic name: Mycophenolate Mofetil (MMF)
Approved indications: The prevention of rejection of kidney, heart and liver transplants.
Clinical study summary: Randomized, double-blind placebo controlled clinical trial designed to investigate the efficacy and safety of CellCept for patients with myasthenia gravis over a treatment period over 36 weeks.
Primary endpoint: The primary endpoint of responder status encompasses both minimal disease activity and low steroid dose.
Phase of development: Phase III
Trial initiation (first patient enrolled): April 2004
Trial complete: failed to meet both primary and secondary endpoints.
Back to 'Autoimmune Diseases'